| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2019: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Outline of Final Research Achievements |
Actinomycetes are known to conduct a wide variety of secondary metabolisms. Many secondary metabolites have been discovered from actinomycetes and have been used as pharmaceutical drugs. However, genome analysis has revealed that only a few secondary metabolites have been discovered in actinomycetes, and that many potential secondary metabolites have not yet been discovered.
The discovery of such potential secondary metabolites is expected to lead to the development of new drugs. Therefore, we have established a "combined-culture" as a method to activate potential secondary metabolisms, and have already discovered over 35 new secondary metabolites. This method was inspired by the soil environment in which actinomycetes generally live, and it activates the potential secondary metabolism of actinomycetes by co-culture of mycolic acid-containing bacteria (MACB) and actinomycetes. In this study, we investigated the mode of action in the combined-culture.
|
